BMEA → $7.00 by Nov 21, 2026.

Out on Yahoo Finance: [https://finance.yahoo.com/markets/stocks/articles/citi-predicts-410-rally-2-180500861.html](https://finance.yahoo.com/markets/stocks/articles/citi-predicts-410-rally-2-180500861.html) BMEA is sitting at just $1.37, and Citi thinks there could be a BIG opportunity here. The catalyst? BMF-650. This is Biomea’s oral GLP-1 candidate, and the company is expected to drop 28-day weight-loss data from its Phase 1 study in Q3. If those numbers deliver, this tiny biotech could have a lot more eyes on it. And Citi analyst Yigal Nochomovitz likes what he’s seeing so far. BMF-650 is being developed as a potentially …